Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pergolide helps manage equine PPID, study finds
The pergolide treatment did not have any effect on horses which were diagnosed with ID only.
The drug reduced blood insulin levels in horses with both PPID and ID.

A new study has highlighted the benefits of using pergolide mesylate to treat horses diagnosed with pituitary pars intermedia dysfunction (PPID).

The drug, which is already commonly used for treating the condition, proved to be effective in reducing the amount of insulin produced by horses when eating.

PPID, also known as Cushing's syndrome, affects the pituitary gland at the base of a horse's brain which produces hormones in response to brain signals. When damaged due to PPID, there can be excessive production of normal hormones, leading to issues such as laminitis and weight loss.

The risk of developing laminitis is higher in horses also diagnosed with insulin dysregulation (ID). A high concentration of insulin is now recognised as the leading cause of laminitis in the UK.

A research project, published by the University of Melbourne, sought to investigate how effective pergolide was at managing the clinical signs of PPID.

The study saw 16 senior horses (eight with PPID and ID, eight with ID only) take part in a standard meal test. Researchers measured the horses' insulin concentration before and after they had eaten a high starch meal.

All of the horses did the standard meal test twice, once after four weeks of pergolide treatment and once without pergolide treatment.

The results revealed that pergolide was an effective treatment for horses with both PPID and ID. Horses treated with pergolide recorded blood insulin levels at the same level as horses that only had ID.

However, the pergolide treatment did not have any effect on horses which were diagnosed with ID only. Researchers say that this highlights the importance of testing for PPID and ID separately, as treating one may not manage the other.

The study also found that, even when treated with pergolide, the horses diagnosed with PPID or ID still produced more insulin from starchy, sugary meals than healthy horses. Researchers say that a low sugar and starch diet remains vital for managing horses with PPID and ID.

The full study has been published in the Equine Veterinary Journal.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.